Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

Status Completed

Clinical Trial Summary

This pilot study will make a preliminary determination of the safety of ustekinumab in patients with Primary Sjogren's Syndrome (PSS) and assess the response of systemic measures of inflammation (biomarkers).

Clinical Trial Description

This is a single-center, open label, pilot trial of ustekinumab in patients with Primary Sjögren's Syndrome (PSS). Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04093531
Study type	Interventional
Source	University of Rochester
Contact
Status	Completed
Phase	Phase 1
Start date	January 15, 2020
Completion date	May 11, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03140111` - LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients	N/A
Not yet recruiting	`NCT06049368` - 68Ga-P16-093 PET/CT Imaging in the Salivary Gland	Phase 1/Phase 2
Not yet recruiting	`NCT03614299` - Eye Dryness Evaluation in Primary Sjögren's Syndrome
Not yet recruiting	`NCT03126383` - Inflammatory Myopathies in Primary Sjögren's Syndrome	N/A
Recruiting	`NCT04830644` - A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.	Phase 2
Not yet recruiting	`NCT03765593` - Biomarkers in Primary Sjögren's Syndrome
Completed	`NCT01081184` - Neurotrophins Implications in Primary Sjögren Syndrome	N/A
Completed	`NCT05670535` - Sjögren and Gynecologic Considerations
Completed	`NCT03226444` - Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome	Phase 1/Phase 2
Completed	`NCT04816370` - Effects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions	N/A
Completed	`NCT05380804` - Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
Terminated	`NCT04700280` - A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)	Phase 2
Completed	`NCT03130062` - Resistance Exercise in Woman With Primary Sjörgen Syndrome.	N/A
Recruiting	`NCT03509064` - Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
Completed	`NCT04224454` - Vaccine Coverage and Primary Sjögren'Syndrome
Completed	`NCT04960605` - Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome	N/A
Recruiting	`NCT06361745` - Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases	N/A